AR084408A1 - Compuestos de purina y 7-deazapurina substituidos - Google Patents
Compuestos de purina y 7-deazapurina substituidosInfo
- Publication number
- AR084408A1 AR084408A1 ARP110104537A ARP110104537A AR084408A1 AR 084408 A1 AR084408 A1 AR 084408A1 AR P110104537 A ARP110104537 A AR P110104537A AR P110104537 A ARP110104537 A AR P110104537A AR 084408 A1 AR084408 A1 AR 084408A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- aryl
- halo
- alkynyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 title abstract 2
- 150000003212 purines Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 12
- 125000005843 halogen group Chemical group 0.000 abstract 11
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 9
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 9
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 8
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 7
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 7
- 125000001424 substituent group Chemical group 0.000 abstract 6
- -1 cyano, hydroxyl Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- SWKAVEUTKGKHSR-UHFFFAOYSA-N 3-(benzylsulfamoyl)-4-bromo-n-(4-bromophenyl)benzamide Chemical compound C1=CC(Br)=CC=C1NC(=O)C1=CC=C(Br)C(S(=O)(=O)NCC=2C=CC=CC=2)=C1 SWKAVEUTKGKHSR-UHFFFAOYSA-N 0.000 abstract 2
- 125000005647 linker group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 abstract 1
- 102100039489 Histone-lysine N-methyltransferase, H3 lysine-79 specific Human genes 0.000 abstract 1
- 101000963360 Homo sapiens Histone-lysine N-methyltransferase, H3 lysine-79 specific Proteins 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- ARIRIZBKMKMEBD-UHFFFAOYSA-N n-hydroxy-2-[4-(4-phenoxy-benzenesulfonyl)-tetrahydro-pyran-4-yl]-acetamide Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1S(=O)(=O)C1(CC(=O)NO)CCOCC1 ARIRIZBKMKMEBD-UHFFFAOYSA-N 0.000 abstract 1
- 230000019639 protein methylation Effects 0.000 abstract 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 abstract 1
- 229910052703 rhodium Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41966110P | 2010-12-03 | 2010-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR084408A1 true AR084408A1 (es) | 2013-05-15 |
Family
ID=45444712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110104537A AR084408A1 (es) | 2010-12-03 | 2011-12-05 | Compuestos de purina y 7-deazapurina substituidos |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US8580762B2 (enExample) |
| EP (1) | EP2646444B1 (enExample) |
| JP (1) | JP5931905B2 (enExample) |
| KR (1) | KR101923746B1 (enExample) |
| CN (1) | CN103391939B (enExample) |
| AR (1) | AR084408A1 (enExample) |
| AU (1) | AU2011336415B2 (enExample) |
| BR (1) | BR112013013659B8 (enExample) |
| CA (1) | CA2819648C (enExample) |
| DK (1) | DK2646444T3 (enExample) |
| ES (1) | ES2577027T3 (enExample) |
| HR (1) | HRP20160655T1 (enExample) |
| IL (1) | IL226651A (enExample) |
| MX (1) | MX2013006251A (enExample) |
| RU (1) | RU2606514C2 (enExample) |
| SI (1) | SI2646444T1 (enExample) |
| TW (1) | TWI537271B (enExample) |
| WO (1) | WO2012075381A1 (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8580762B2 (en) * | 2010-12-03 | 2013-11-12 | Epizyme, Inc. | Substituted purine and 7-deazapurine compounds |
| CA2819620A1 (en) | 2010-12-03 | 2012-06-21 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
| CA2819625A1 (en) | 2010-12-03 | 2012-06-07 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| AU2011336264A1 (en) | 2010-12-03 | 2013-06-20 | Epizyme, Inc. | Carbocycle-substituted purine and 7-deazapurine compounds |
| WO2013055397A1 (en) | 2011-10-14 | 2013-04-18 | Children's Medical Center Corporation | Inhibition and enhancement of reprogramming by chromatin modifying enzymes |
| SI2794627T1 (sl) | 2011-12-22 | 2019-02-28 | Alios Biopharma, Inc. | Substituirani nukleozidi, nukleotidi in njihovi analogi |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| WO2014026198A1 (en) | 2012-08-10 | 2014-02-13 | Epizyme, Inc. | Inhibitors of protein methyltransferase dot1l and methods of use thereof |
| CA2883781A1 (en) | 2012-09-06 | 2014-03-13 | Epizyme, Inc. | Method of treating leukemia |
| WO2014100662A1 (en) * | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Dot1 l inhibitors for use in the treatment of leukemia |
| EP2958921B1 (en) | 2013-02-22 | 2017-09-20 | Pfizer Inc | Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus kinases (jak) |
| US9394258B2 (en) | 2013-03-14 | 2016-07-19 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| AU2014260433A1 (en) | 2013-03-14 | 2015-09-10 | Epizyme, Inc. | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof |
| US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| EP2970136A1 (en) | 2013-03-14 | 2016-01-20 | Epizyme, Inc. | Arginine methyl transferase inhibtors and uses thereof |
| EP2970133B1 (en) | 2013-03-14 | 2018-10-24 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| SG11201506972PA (en) | 2013-03-14 | 2015-10-29 | Epizyme Inc | Arginine methyltransferase inhibitors and uses thereof |
| WO2014153208A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| EP2970134B1 (en) | 2013-03-14 | 2018-02-28 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| US9446064B2 (en) * | 2013-03-14 | 2016-09-20 | Epizyme, Inc. | Combination therapy for treating cancer |
| JP2016517434A (ja) * | 2013-03-14 | 2016-06-16 | エピザイム，インコーポレイティド | 癌を処置するための併用療法 |
| US20160031839A1 (en) | 2013-03-14 | 2016-02-04 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2014152261A1 (en) * | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Substituted 7-deazapurine compounds |
| WO2014144659A1 (en) | 2013-03-14 | 2014-09-18 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| AU2014239516B2 (en) * | 2013-03-15 | 2019-01-24 | Epizyme, Inc. | Injectable formulations for treating cancer |
| CA2903303A1 (en) | 2013-03-15 | 2014-09-25 | Epizyme, Inc. | Methods of synthesizing substituted purine compounds |
| WO2015003131A1 (en) * | 2013-07-03 | 2015-01-08 | Epizyme, Inc. | Substituted purine compounds |
| US9535067B2 (en) | 2013-07-29 | 2017-01-03 | Dana-Farber Cancer Institute, Inc. | DOT1L probes |
| US10407732B2 (en) | 2013-08-02 | 2019-09-10 | Memorial Sloan Kettering Cancer Center | Methods for the detection and treatment of leukemias that are responsive to DOT1L inhibition |
| WO2015073706A1 (en) * | 2013-11-13 | 2015-05-21 | Epizyme, Inc. | Methods for treating cancer |
| US20170198006A1 (en) * | 2014-06-25 | 2017-07-13 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| EP3180344B1 (en) | 2014-08-12 | 2019-09-18 | Pfizer Inc | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
| WO2016025635A2 (en) * | 2014-08-13 | 2016-02-18 | Epizyme, Inc. | Combination therapy for treating cancer |
| US9458165B2 (en) | 2014-08-27 | 2016-10-04 | Dana-Farber Cancer Institute, Inc. | DOT1L inhibitors |
| AU2015317509A1 (en) * | 2014-09-17 | 2017-03-16 | Epizyme, Inc. | Injectable formulations for treating cancer |
| WO2016043874A2 (en) * | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Combination therapy for treating cancer |
| EP3200826B1 (en) * | 2014-09-30 | 2021-04-21 | Vecht-lifshitz, Susan Eve | Pharmaceutical compositions for treating ebola virus disease |
| US20180028552A1 (en) * | 2015-01-30 | 2018-02-01 | Epizyme, Inc. | Combination therapy for treating cancer |
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| CA3012649A1 (en) | 2016-01-26 | 2017-08-03 | Memorial Sloan-Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in npm1 mutant leukemia |
| KR102646126B1 (ko) | 2016-03-15 | 2024-03-11 | 오리존 지노믹스 에스.에이. | 혈액 악성 종양의 치료를 위한 lsd1 억제제의 조합물 |
| AU2017233898B2 (en) | 2016-03-15 | 2022-12-15 | Oryzon Genomics, S.A. | Combinations of LSD1 inhibitors for use in the treatment of solid tumors |
| CN106432095B (zh) * | 2016-09-09 | 2019-04-16 | 东南大学 | 匹莫苯丹关键中间体6-(3,4-二氨基苯基)-5-甲基-4,5-二氢哒嗪-3(2h)-酮的制备 |
| US11944627B2 (en) | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
| CN109748944B (zh) * | 2017-11-03 | 2021-12-10 | 中国科学院上海药物研究所 | 5’-脱氧-5’-异丙基取代氨基核苷类化合物、其制备方法和用途 |
| CN109748943A (zh) * | 2017-11-03 | 2019-05-14 | 中国科学院上海药物研究所 | 2’-c-甲基取代核苷类化合物及其制备与用途 |
| WO2019112719A1 (en) * | 2017-12-05 | 2019-06-13 | Angex Pharmaceutical, Inc. | Heterocyclic compounds as prmt5 inhibitors |
| KR102118891B1 (ko) | 2018-10-04 | 2020-06-04 | 성균관대학교산학협력단 | 매소니아노사이드 b를 유효성분으로 포함하는 혼합 직계성 백혈병 유전자 재배열 동반 백혈병 예방 및 치료용 약학적 조성물 |
| EP3908583A4 (en) | 2019-01-09 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Dot1l degraders and uses thereof |
| JP2022523860A (ja) * | 2019-03-11 | 2022-04-26 | コラボレイティブ メディシナル デベロップメント， エルエルシー | フェロトーシス関連障害の処置のための複素芳香族およびヘテロ二環式芳香族誘導体 |
| CN110092804A (zh) * | 2019-03-29 | 2019-08-06 | 广州盈升生物科技有限公司 | 一种含双环基团的嘌呤化合物及其制备方法 |
| US11198699B2 (en) | 2019-04-02 | 2021-12-14 | Aligos Therapeutics, Inc. | Compounds targeting PRMT5 |
| CN113024620B (zh) * | 2021-03-11 | 2023-02-28 | 沈阳药科大学 | 一种嘌呤衍生物及其制备方法和用途 |
| WO2022271540A1 (en) * | 2021-06-21 | 2022-12-29 | Mayo Foundation For Medical Education And Research | Inhibitors of dot1l |
| CA3226162A1 (en) | 2021-07-09 | 2023-01-12 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
| AU2022316195A1 (en) * | 2021-07-19 | 2024-01-04 | Dana-Farber Cancer Institute, Inc. | Targeting dot1l and smarca4/2 for the treatment of mllr leukemia |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US20020127598A1 (en) | 2000-03-27 | 2002-09-12 | Wenqiang Zhou | Solution-phase combinatorial library synthesis and pharmaceutically active compounds produced thereby |
| EP1138689A1 (en) | 2000-03-28 | 2001-10-04 | Roche Diagnostics GmbH | N8- and C8-linked purine bases as universal nucleosides used for oligonucleotide hybridization |
| EP1138688A1 (en) | 2000-03-28 | 2001-10-04 | Roche Diagnostics GmbH | N8- and C8- linked purine bases as universal nucleosides used for oligonucleotide hybridization |
| US6534651B2 (en) | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
| US20040043959A1 (en) | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
| WO2004007512A2 (en) * | 2002-07-16 | 2004-01-22 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| AU2002951247A0 (en) * | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
| NZ538457A (en) | 2002-09-30 | 2008-04-30 | Genelabs Tech Inc | Nucleoside derivatives for treating hepatitis C virus infection |
| GB0301450D0 (en) * | 2003-01-22 | 2003-02-19 | Medical Res Council | Protein crystal structure |
| RU2354655C2 (ru) * | 2003-12-19 | 2009-05-10 | Ф.Хоффманн-Ля Рош Аг | Ингибиторы сомт |
| SG155182A1 (en) | 2004-08-02 | 2009-09-30 | Univ Virginia | 2-propynyl adenosine analogs with modified 5æ-ribose groups having a2a agonist activity |
| WO2006028618A1 (en) * | 2004-08-02 | 2006-03-16 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
| US8058762B2 (en) * | 2005-01-19 | 2011-11-15 | Daikin Industries, Ltd. | Rotor, axial gap type motor, method of driving motor, and compressor |
| EP1844062A2 (en) | 2005-01-21 | 2007-10-17 | Methylgene, Inc. | Inhibitors of dna methyltransferase |
| EP1848718B1 (en) | 2005-02-04 | 2012-08-01 | Millennium Pharmaceuticals, Inc. | Inhibitors of e1 activating enzymes |
| WO2006113458A1 (en) | 2005-04-15 | 2006-10-26 | Bristol-Myers Squibb Company | Heterocyclic inhibitors of protein arginine methyl transferases |
| WO2006113615A2 (en) | 2005-04-15 | 2006-10-26 | Sloan-Kettering Institute For Cancer Research | Anti-microbial agents and uses thereof |
| CN106008512B (zh) | 2006-02-02 | 2019-03-12 | 千禧药品公司 | E1活化酶抑制剂 |
| US8058258B2 (en) | 2006-03-02 | 2011-11-15 | Agency For Science, Technology And Research | Methods for cancer therapy and stem cell modulation |
| GB0607953D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| US8188063B2 (en) | 2006-06-19 | 2012-05-29 | University Of Virginia Patent Foundation | Use of adenosine A2A modulators to treat spinal cord injury |
| US20080132525A1 (en) | 2006-12-04 | 2008-06-05 | Methylgene Inc. | Inhibitors of DNA Methyltransferase |
| US20080312160A1 (en) | 2007-04-09 | 2008-12-18 | Guerrant Richard L | Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist |
| CN101417967A (zh) | 2007-10-26 | 2009-04-29 | 浙江海正药业股份有限公司 | 组蛋白去乙酰酶抑制剂、其组合物及其应用 |
| PT2463282E (pt) | 2007-11-05 | 2013-11-11 | Novartis Ag | Derivados de 4-benzilamino-1-carboxiacil-piperidina como inibidores de cetp úteis para o tratamento de doenças tais como hiperlipidemia ou arteriosclerose |
| CA2711495A1 (en) | 2008-01-09 | 2009-07-16 | Pgxhealth Llc | Intrathecal treatment of neuropathic pain with a2ar agonists |
| WO2010015643A1 (en) | 2008-08-06 | 2010-02-11 | Novartis Ag | New antiviral modified nucleosides |
| US20110171192A1 (en) | 2008-09-05 | 2011-07-14 | Hiroshi Tomiyama | Substituted amine derivative and medicinal composition comprising same as the active ingredient |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| EA201290073A1 (ru) * | 2009-08-24 | 2013-01-30 | Эсэпиен Фармасьютикалз, Инк. | Соединения мочевины, содержащие 5,6-бициклический гетероарил, как ингибиторы киназ |
| US8580762B2 (en) * | 2010-12-03 | 2013-11-12 | Epizyme, Inc. | Substituted purine and 7-deazapurine compounds |
| AU2011336264A1 (en) | 2010-12-03 | 2013-06-20 | Epizyme, Inc. | Carbocycle-substituted purine and 7-deazapurine compounds |
| CA2819625A1 (en) | 2010-12-03 | 2012-06-07 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| CA2819620A1 (en) | 2010-12-03 | 2012-06-21 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
| CA2883781A1 (en) * | 2012-09-06 | 2014-03-13 | Epizyme, Inc. | Method of treating leukemia |
| US9446064B2 (en) * | 2013-03-14 | 2016-09-20 | Epizyme, Inc. | Combination therapy for treating cancer |
| CA2903303A1 (en) | 2013-03-15 | 2014-09-25 | Epizyme, Inc. | Methods of synthesizing substituted purine compounds |
| US10407732B2 (en) * | 2013-08-02 | 2019-09-10 | Memorial Sloan Kettering Cancer Center | Methods for the detection and treatment of leukemias that are responsive to DOT1L inhibition |
| WO2015073706A1 (en) * | 2013-11-13 | 2015-05-21 | Epizyme, Inc. | Methods for treating cancer |
-
2011
- 2011-12-02 US US13/310,157 patent/US8580762B2/en not_active Expired - Fee Related
- 2011-12-02 RU RU2013130250A patent/RU2606514C2/ru active
- 2011-12-02 KR KR1020137017337A patent/KR101923746B1/ko not_active Expired - Fee Related
- 2011-12-02 JP JP2013542201A patent/JP5931905B2/ja not_active Expired - Fee Related
- 2011-12-02 DK DK11804836.2T patent/DK2646444T3/da active
- 2011-12-02 MX MX2013006251A patent/MX2013006251A/es active IP Right Grant
- 2011-12-02 ES ES11804836.2T patent/ES2577027T3/es active Active
- 2011-12-02 EP EP11804836.2A patent/EP2646444B1/en active Active
- 2011-12-02 CA CA2819648A patent/CA2819648C/en active Active
- 2011-12-02 SI SI201130856A patent/SI2646444T1/sl unknown
- 2011-12-02 BR BR112013013659A patent/BR112013013659B8/pt not_active IP Right Cessation
- 2011-12-02 CN CN201180066760.7A patent/CN103391939B/zh not_active Expired - Fee Related
- 2011-12-02 WO PCT/US2011/063044 patent/WO2012075381A1/en not_active Ceased
- 2011-12-02 HR HRP20160655TT patent/HRP20160655T1/hr unknown
- 2011-12-02 AU AU2011336415A patent/AU2011336415B2/en not_active Ceased
- 2011-12-05 TW TW100144669A patent/TWI537271B/zh not_active IP Right Cessation
- 2011-12-05 AR ARP110104537A patent/AR084408A1/es active IP Right Grant
-
2013
- 2013-05-30 IL IL226651A patent/IL226651A/en active IP Right Grant
- 2013-10-16 US US14/055,510 patent/US9096634B2/en active Active
-
2015
- 2015-06-26 US US14/752,023 patent/US20150366893A1/en not_active Abandoned
-
2017
- 2017-11-03 US US15/802,979 patent/US20180280422A1/en not_active Abandoned
-
2020
- 2020-06-10 US US16/897,690 patent/US20210252035A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR084408A1 (es) | Compuestos de purina y 7-deazapurina substituidos | |
| ES2580481T3 (es) | Derivados de aminoquinazolina y sus sales, y métodos de uso | |
| AR059064A1 (es) | Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer. | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| MX2015004771A (es) | Metodos para tratar cancer. | |
| AR085489A1 (es) | Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias | |
| AR124662A2 (es) | Formulaciones inmunosupresoras | |
| AR091156A1 (es) | Nucleosidos de espirooxetano de uracilo | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| AR084553A1 (es) | DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| MX2020012695A (es) | Compuestos de benceno substituidos con arilo o heteroarilo. | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR097431A1 (es) | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim | |
| EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
| AR071480A1 (es) | Compuesto de 1- ciano -3- pirrolidinil -bencenosulfonamida composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar la enfermedad pulmonar obstructiva cronica (copd ) | |
| AR086676A1 (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de fosfodiesterasa | |
| AR094762A1 (es) | Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo | |
| AR106865A1 (es) | Piridinas sustituidas y métodos de uso | |
| AR082844A1 (es) | Derivados de piperidina y su uso para el tratamiento de desordenes metabolicos | |
| AR083268A1 (es) | Conjugado de naloxol-peg cristalino | |
| AR091455A1 (es) | Derivados 1,3-dihidro-2h-benzimidazol-2-ona sustituidos con heterociclos como agentes antivirales para el virus sincicial respiratorio | |
| ES2526902T3 (es) | Procesos de producción de inhibidores de la girasa y topoisomerasa IV | |
| UY33490A (es) | Ésteres de quinolina nuevos útiles para el tratamiento de trastornos cutáneos. | |
| AR084505A1 (es) | Derivados de 5-metil-1-(naftalen-2-il)-1h-pirazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |